Skip to main content

Drug Interactions between infigratinib and Xalkori

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

crizotinib infigratinib

Applies to: Xalkori (crizotinib) and infigratinib

Crizotinib may significantly increase the blood levels of infigratinib. This may increase the frequency and severity of serious side effects such as infections; decreased red blood cell, white blood cell, and platelet counts; fever; abdominal pain; increased blood calcium and phosphate levels above normal; eye and vision problems; mouth sores and inflammation; diarrhea; redness, swelling, peeling, or tenderness, mainly on the hands and feet ('hand-foot syndrome'); nails separating from the bed or poor formation of the nail; and changes in kidney function blood tests. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Major

crizotinib food

Applies to: Xalkori (crizotinib)

Do not consume grapefruit or grapefruit juice during treatment with crizotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of crizotinib to dangerous levels and cause an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats during treatment with crizotinib. You may take crizotinib with or without food, but take it the same time each day. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

infigratinib food

Applies to: infigratinib

Infigratinib should be taken on an empty stomach, at least 1 hour before or 2 hours after food. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with infigratinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of infigratinib. This may increase the frequency and severity of serious side effects such as infections; decreased red blood cell, white blood cell, and platelet counts; fever; abdominal pain; increased blood calcium and phosphate levels above normal; eye and vision problems; mouth sores and inflammation; diarrhea; redness, swelling, peeling or tenderness, mainly on the hands and feet ('hand-foot syndrome'); nails separating from the bed or poor formation of the nail; and changes in kidney function blood tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • infigratinib
  • Xalkori (crizotinib)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer